Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Do you like to follow insider trends? If so, here's a list you might be interested in.

We ran a screen on the biotech industry for stocks that are currently highly shorted, with float shorts above 10%. We then screened for those with the confidence of company insiders, with significant net insider purchases over the last six months.

‪Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks top six mentioned below. Analyst ratings sourced from Zacks Investment Research.‬‬

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these stocks are potential short squeeze candidates? Use this list as a starting point for your own analysis.

1. Cerus Corporation (NASDAQ:CERS): Engages in the development and commercialization of the INTERCEPT Blood System. Float short at 16.50%. Over the last six months, insiders were net buyers of 50,000 shares, which represents about 0.11% of the company's 46.63M share float.

2. Cytori Therapeutics, Inc. (NASDAQ:CYTX): Engages in the development, manufacture, and sale of medical products and devices to enable the practice of regenerative medicine. Float short at 16.68%. Over the last six months, insiders were net buyers of 109,198 shares, which represents about 0.24% of the company's 46.29M share float.

3. GTX Inc. (NASDAQ:GTXI): Engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions. Float short at 12.98%. Over the last six months, insiders were net buyers of 30,000 shares, which represents about 0.14% of the company's 21.03M share float.

4. Incyte Corporation (NASDAQ:INCY): Focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Float short at 15.50%. Over the last six months, insiders were net buyers of 4,476,050 shares, which represents about 3.59% of the company's 124.60M share float.

5. PharmAthene, Inc. (NYSEMKT:PIP): Engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. Float short at 11.49%. Over the last six months, insiders were net buyers of 70,000 shares, which represents about 0.18% of the company's 39.96M share float.

6. Seattle Genetics Inc. (NASDAQ:SGEN): Focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Float short at 25.79%. Over the last six months, insiders were net buyers of 1,147,052 shares, which represents about 1.01% of the company's 113.40M share float.

7. SIGA Technologies, Inc. (NASDAQ:SIGA): Engages in the research, discovery, development, and commercialization of novel products for the prevention and treatment of infectious diseases. Float short at 20.47%. Over the last six months, insiders were net buyers of 86,500 shares, which represents about 0.23% of the company's 37.32M share float.

8. Sequenom Inc. (NASDAQ:SQNM): Provides products, services, diagnostic testing, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural and livestock research. Float short at 19.32%. Over the last six months, insiders were net buyers of 96,150 shares, which represents about 0.1% of the company's 98.74M share float.

9. Savient Pharmaceuticals, Inc. (SVNT): Focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. Float short at 40.06%. Over the last six months, insiders were net buyers of 80,500 shares, which represents about 0.15% of the company's 55.48M share float.

10. Theravance Inc. (NASDAQ:THRX): Engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system/pain. Float short at 10.23%. Over the last six months, insiders were net buyers of 126,584 shares, which represents about 0.24% of the company's 51.96M share float.

11. ViroPharma Inc. (VPHM): Engages in the development and commercialization of products that address serious diseases with a focus on products used by physician specialists or in hospital settings in the United States and internationally. Float short at 10.93%. Over the last six months, insiders were net buyers of 2,020,227 shares, which represents about 3.09% of the company's 65.45M share float.

12. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Focuses on the development and commercialization of in-licensed cancer drugs in North America. Float short at 13.31%. Over the last six months, insiders were net buyers of 1,351,460 shares, which represents about 2.45% of the company's 55.23M share float.

*Insider data sourced from Yahoo Finance, all other data sourced from Finviz.

Source: 12 Highly Shorted Biotech Stocks Being Snapped Up By Insiders